The effect of menopausal hormone therapy on thyroid cancer survivors from the National Health Insurance Database in South Korea cohort

IF 2.1 4区医学 Q2 OBSTETRICS & GYNECOLOGY

European journal of obstetrics, gynecology, and reproductive biology Pub Date : 2025-04-19 DOI:10.1016/j.ejogrb.2025.113983

Jin-Sung Yuk , Jin Li Lee , Yeonjin Shin , Gwan Hee Han , Sang-Hee Yoon , Myoung Hwan Kim , Ji Hyun Noh , Yujin Lee , Jungbin Kim , Sam-Youl Yoon , Hyunjin Cho , Keunho Yang , Byung Noe Bae , Ki Whan Kim , Geumhee Gwak

{"title":"The effect of menopausal hormone therapy on thyroid cancer survivors from the National Health Insurance Database in South Korea cohort","authors":"Jin-Sung Yuk , Jin Li Lee , Yeonjin Shin , Gwan Hee Han , Sang-Hee Yoon , Myoung Hwan Kim , Ji Hyun Noh , Yujin Lee , Jungbin Kim , Sam-Youl Yoon , Hyunjin Cho , Keunho Yang , Byung Noe Bae , Ki Whan Kim , Geumhee Gwak","doi":"10.1016/j.ejogrb.2025.113983","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>There is a lack of research on how menopausal hormone therapy (MHT) affects the prognosis of postmenopausal thyroid cancer (TC) survivors. This study aimed to evaluate the association between MHT and the risk of death in postmenopausal TC survivors.</div></div><div><h3>Methods</h3><div>This retrospective cohort study used the data of women with the diagnostic code for TC from the Korean National Health Insurance Database between 2007 and 2021. The postmenopausal women with TC who received radical treatment such as surgery or/and radioactive iodine therapy were divided into two groups – MHT group and non-MHT group – according to whether or not they received MHT after TC treatment. The risk of death in TC survivors was analysed according to the type and duration of the MHT regimen.</div></div><div><h3>Results</h3><div>Among postmenopausal TC survivors, the risk of death did not differ between the women with MHT duration > 5 years and the non-MHT group, with a hazard ratio (HR) of 0.964 [95 % confidence interval (CI) 0.697–1.334] (<em>p</em> = 0.826). However, MHT duration < 5 years was associated with increased risk of death, with the MHT group having an HR of 1.744 (95 % CI 1.105–2.753) (<em>p</em> = 0.017) compared with the non-MHT group. A trend was observed towards increased risk of death in women with MHT duration ≤ 6 months, with an HR of 1.703 (95 % CI 0.98–2.962) (<em>p</em> = 0.059). The risk of death did not differ between women with MHT duration > 6 months and women in the non-MHT group (HR 1.205, 95 % CI 0.79–1.839) (<em>p</em> = 0.064). In analyses by MHT regimen, no increase in the risk of death was observed for any MHT regimen for any duration.</div></div><div><h3>Conclusion</h3><div>The risk of death in postmenopausal TC survivors who used MHT for > 5 years did not differ from that of their counterparts who did not use MHT. However, postmenopausal TC survivors who used MHT for < 5 years, particularly those who used MHT for < 6 months, had a higher risk of death than their counterparts who did not use MHT.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"310 ","pages":"Article 113983"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211525002520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

There is a lack of research on how menopausal hormone therapy (MHT) affects the prognosis of postmenopausal thyroid cancer (TC) survivors. This study aimed to evaluate the association between MHT and the risk of death in postmenopausal TC survivors.

Methods

This retrospective cohort study used the data of women with the diagnostic code for TC from the Korean National Health Insurance Database between 2007 and 2021. The postmenopausal women with TC who received radical treatment such as surgery or/and radioactive iodine therapy were divided into two groups – MHT group and non-MHT group – according to whether or not they received MHT after TC treatment. The risk of death in TC survivors was analysed according to the type and duration of the MHT regimen.

Results

Among postmenopausal TC survivors, the risk of death did not differ between the women with MHT duration > 5 years and the non-MHT group, with a hazard ratio (HR) of 0.964 [95 % confidence interval (CI) 0.697–1.334] (p = 0.826). However, MHT duration < 5 years was associated with increased risk of death, with the MHT group having an HR of 1.744 (95 % CI 1.105–2.753) (p = 0.017) compared with the non-MHT group. A trend was observed towards increased risk of death in women with MHT duration ≤ 6 months, with an HR of 1.703 (95 % CI 0.98–2.962) (p = 0.059). The risk of death did not differ between women with MHT duration > 6 months and women in the non-MHT group (HR 1.205, 95 % CI 0.79–1.839) (p = 0.064). In analyses by MHT regimen, no increase in the risk of death was observed for any MHT regimen for any duration.

Conclusion

The risk of death in postmenopausal TC survivors who used MHT for > 5 years did not differ from that of their counterparts who did not use MHT. However, postmenopausal TC survivors who used MHT for < 5 years, particularly those who used MHT for < 6 months, had a higher risk of death than their counterparts who did not use MHT.

查看原文本刊更多论文

绝经期激素治疗对来自韩国国家健康保险数据库的甲状腺癌幸存者的影响

目的绝经期激素治疗（MHT）对绝经后甲状腺癌（TC）幸存者预后的影响尚缺乏研究。本研究旨在评估MHT与绝经后TC幸存者死亡风险之间的关系。方法本回顾性队列研究使用韩国国民健康保险数据库2007年至2021年诊断代码为TC的妇女数据。绝经后接受手术或/或放射性碘治疗等根治性治疗的TC妇女，根据TC治疗后是否接受MHT，分为MHT组和非MHT组。根据MHT方案的类型和持续时间分析TC幸存者的死亡风险。结果在绝经后TC幸存者中，MHT持续时间和时间的妇女死亡风险无差异；5年和非mht组，风险比（HR）为0.964[95%可信区间（CI） 0.697-1.334] （p = 0.826）。然而，MHT持续时间<；5年与死亡风险增加相关，与非MHT组相比，MHT组的HR为1.744 (95% CI 1.105-2.753) （p = 0.017）。MHT持续时间≤6个月的妇女有死亡风险增加的趋势，相对危险度为1.703 (95% CI 0.98-2.962) （p = 0.059）。MHT持续时间不同的妇女死亡风险无差异；非mht组6个月和女性（HR 1.205, 95% CI 0.79-1.839）（p = 0.064）。在MHT方案的分析中，没有观察到任何MHT方案在任何持续时间内的死亡风险增加。结论绝经后TC患者接受MHT治疗后死亡风险降低；与未使用MHT的对照组相比，5年的寿命没有差异。然而，使用MHT治疗的绝经后TC幸存者；5年，特别是那些使用MHT的人。6个月后，他们的死亡风险高于未使用MHT的对照组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of obstetrics, gynecology, and reproductive biology 医学-妇产科学

CiteScore

4.60

自引率

3.80%

发文量

898

审稿时长

8.3 weeks

期刊介绍： The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.